Psoriasis is the most common chronic inflammatory skin disease; 15–30% of patients with psoriasis have psoriatic arthritis.1 The interleukin (IL) 23 and IL17 pathway has a crucial role in pathogenesis, and inhibitors of the IL17 pathway have rewritten treatment paradigms especially for psoriasis control, with up to 50% of patients achieving at least 100% reductions in Psoriasis Area and Severity Index (PASI) scores (PASI100).2 Before IL17 inhibitors were introduced, around 60% of patients achieving a 75% reduction in PASI scores was the best outcome that could be expected.